Jun 11, 2026 07:30AM
Jun 10, 2026 07:30AM
Jun 10, 2026 07:30AM
Jun 18, 2025 07:00AM
Jun 18, 2025 07:00AM
Dec 11, 2024 07:00AM
Nov 6, 2024 07:14PM Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 30, 2024 09:00AM
Sep 28, 2022 07:00AM
Aug 3, 2022 08:00AM
Jul 6, 2022 08:00AM
Jun 27, 2022 08:00AM
Jun 16, 2022 02:14PM
Jun 16, 2022 08:00AM Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
Jun 1, 2022 08:00AM
May 24, 2022 11:06AM
May 24, 2022 11:04AM
May 19, 2022 09:00AM
Jan 18, 2022 08:30AM
Jan 18, 2022 08:30AM
Jan 6, 2022 08:30AM Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patie
Jan 6, 2022 08:30AM
Dec 13, 2021 08:00AM
Dec 13, 2021 08:00AM
Nov 11, 2021 09:00AM
Nov 11, 2021 09:00AM
Nov 3, 2021 09:03AM
Nov 3, 2021 09:00AM European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma
Nov 3, 2021 09:00AM
Oct 28, 2021 08:02AM
Oct 28, 2021 08:00AM
Oct 28, 2021 08:00AM
Oct 28, 2021 07:02AM
Oct 28, 2021 07:00AM
Oct 28, 2021 07:00AM Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute M
Oct 18, 2021 04:30PM
Sep 27, 2021 08:00AM
Sep 27, 2021 08:00AM
Aug 26, 2021 08:00AM
Aug 26, 2021 08:00AM
Aug 25, 2021 10:02AM
Aug 25, 2021 10:00AM Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Bi
Aug 25, 2021 10:00AM
Aug 17, 2021 10:11AM
Jul 1, 2021 08:01AM
Jul 1, 2021 08:00AM
Jul 1, 2021 08:00AM
Jun 30, 2021 08:00AM
Jun 30, 2021 08:00AM Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncolo
Jun 29, 2021 11:01AM

325,591 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All